151 related articles for article (PubMed ID: 8118023)
1. Intensive therapy with cyclophosphamide, carmustine, etoposide +/- cisplatin, and autologous bone marrow transplantation for Hodgkin's disease in first relapse after combination chemotherapy.
Reece DE; Connors JM; Spinelli JJ; Barnett MJ; Fairey RN; Klingemann HG; Nantel SH; O'Reilly S; Shepherd JD; Sutherland HJ
Blood; 1994 Mar; 83(5):1193-9. PubMed ID: 8118023
[TBL] [Abstract][Full Text] [Related]
2. High-dose cyclophosphamide, carmustine (BCNU), and etoposide (VP16-213) with or without cisplatin (CBV +/- P) and autologous transplantation for patients with Hodgkin's disease who fail to enter a complete remission after combination chemotherapy.
Reece DE; Barnett MJ; Shepherd JD; Hogge DE; Klasa RJ; Nantel SH; Sutherland HJ; Klingemann HG; Fairey RN; Voss NJ
Blood; 1995 Jul; 86(2):451-6. PubMed ID: 7541661
[TBL] [Abstract][Full Text] [Related]
3. Intensive chemotherapy with cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation for relapsed Hodgkin's disease.
Reece DE; Barnett MJ; Connors JM; Fairey RN; Fay JW; Greer JP; Herzig GP; Herzig RH; Klingemann HG; LeMaistre CF
J Clin Oncol; 1991 Oct; 9(10):1871-9. PubMed ID: 1919637
[TBL] [Abstract][Full Text] [Related]
4. High-dose chemotherapy with or without total body irradiation followed by autologous bone marrow and/or peripheral blood stem cell transplantation for patients with relapsed and refractory Hodgkin's disease: results in 85 patients with analysis of prognostic factors.
Nademanee A; O'Donnell MR; Snyder DS; Schmidt GM; Parker PM; Stein AS; Smith EP; Molina A; Stepan DE; Somlo G
Blood; 1995 Mar; 85(5):1381-90. PubMed ID: 7858268
[TBL] [Abstract][Full Text] [Related]
5. High-dose cyclophosphamide, carmustine, and etoposide with autologous transplantation in Hodgkin's disease: a prognostic model for treatment outcomes.
Wheeler C; Eickhoff C; Elias A; Ibrahim J; Ayash L; McCauley M; Mauch P; Schwartz G; Eder JP; Mazanet R; Ferrara J; Rimm IJ; Guinan E; Bierer B; Gilliland G; Churchill WH; Ault K; Parsons S; Antman K; Schnipper L; Tepler I; Gaynes L; Frei E; Kadin M; Antin J
Biol Blood Marrow Transplant; 1997 Jun; 3(2):98-106. PubMed ID: 9267670
[TBL] [Abstract][Full Text] [Related]
6. Double high-dose therapy for Hodgkin's disease with dose-intensive cyclophosphamide, etoposide, and cisplatin (DICEP) prior to high-dose melphalan and autologous stem cell transplantation.
Stewart DA; Guo D; Glück S; Morris D; Chaudhry A; deMetz C; Klassen J; Brown CB; Russell JA
Bone Marrow Transplant; 2000 Aug; 26(4):383-8. PubMed ID: 10982284
[TBL] [Abstract][Full Text] [Related]
7. High-dose cyclophosphamide, carmustine, and etoposide followed by allogeneic bone marrow transplantation in patients with lymphoid malignancies who had received prior dose-limiting radiation therapy.
Demirer T; Weaver CH; Buckner CD; Petersen FB; Bensinger WI; Sanders J; Clift RA; Lilleby K; Anasetti C; Martin P
J Clin Oncol; 1995 Mar; 13(3):596-602. PubMed ID: 7884421
[TBL] [Abstract][Full Text] [Related]
8. Prognostic factors for response and survival after high-dose cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation for relapsed Hodgkin's disease.
Jagannath S; Armitage JO; Dicke KA; Tucker SL; Velasquez WS; Smith K; Vaughan WP; Kessinger A; Horwitz LJ; Hagemeister FB
J Clin Oncol; 1989 Feb; 7(2):179-85. PubMed ID: 2644397
[TBL] [Abstract][Full Text] [Related]
9. High-dose chemotherapy followed by autologous hematopoietic rescue for Hodgkin's disease patients following first relapse after chemotherapy.
Bierman PJ; Anderson JR; Freeman MB; Vose JM; Kessinger A; Bishop MR; Armitage JO
Ann Oncol; 1996 Feb; 7(2):151-6. PubMed ID: 8777171
[TBL] [Abstract][Full Text] [Related]
10. Regimen-related toxicity and non-relapse mortality with high-dose cyclophosphamide, carmustine (BCNU) and etoposide (VP16-213) (CBV) and CBV plus cisplatin (CBVP) followed by autologous stem cell transplantation in patients with Hodgkin's disease.
Reece DE; Nevill TJ; Sayegh A; Spinelli JJ; Brockington DA; Barnett MJ; Klingemann HG; Connors JM; Nantel SH; Shepherd JD; Sutherland HJ; Voss NJ; Fairey RN; O'Reilly SE; Phillips GL
Bone Marrow Transplant; 1999 Jun; 23(11):1131-8. PubMed ID: 10382952
[TBL] [Abstract][Full Text] [Related]
11. Cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation in refractory Hodgkin's disease and non-Hodgkin's lymphoma: a dose-finding study.
Wheeler C; Antin JH; Churchill WH; Come SE; Smith BR; Bubley GJ; Rosenthal DS; Rappaport JM; Ault KA; Schnipper LE
J Clin Oncol; 1990 Apr; 8(4):648-56. PubMed ID: 2313334
[TBL] [Abstract][Full Text] [Related]
12. The Stanford experience with high-dose etoposide cytoreductive regimens and autologous bone marrow transplantation in Hodgkin's disease and non-Hodgkin's lymphoma: preliminary data.
Horning SJ; Chao NJ; Negrin RS; Hoppe RT; Kwak LW; Long GD; Stallbaum B; O'Connor P; Blume KG
Ann Oncol; 1991 Jan; 2 Suppl 1():47-50. PubMed ID: 2043498
[TBL] [Abstract][Full Text] [Related]
13. Incidence of post transplant myelodysplasia/acute leukemia in non-Hodgkin's lymphoma patients compared with Hodgkin's disease patients undergoing autologous transplantation following cyclophosphamide, carmustine, and etoposide (CBV).
Wheeler C; Khurshid A; Ibrahim J; Elias A; Mauch P; Ault K; Antin J
Leuk Lymphoma; 2001 Feb; 40(5-6):499-509. PubMed ID: 11426523
[TBL] [Abstract][Full Text] [Related]
14. High-dose cyclophosphamide, carmustine, and etoposide and autologous bone marrow transplantation for relapsed Hodgkin's disease.
Jagannath S; Dicke KA; Armitage JO; Cabanillas FF; Horwitz LJ; Vellekoop L; Zander AR; Spitzer G
Ann Intern Med; 1986 Feb; 104(2):163-8. PubMed ID: 3511811
[TBL] [Abstract][Full Text] [Related]
15. Cisplatin-CBV with autologous bone marrow transplantation for relapsed Hodgkin's disease.
Spinolo JA; Jagannath S; Velásquez W; Spitzer G; Cabanillas F; Hagemeister F; Horwitz LJ; Dicke KA
Leuk Lymphoma; 1993 Jan; 9(1-2):71-7. PubMed ID: 8477204
[TBL] [Abstract][Full Text] [Related]
16. High-dose chemotherapy and hematopoietic stem cell rescue in patients with relapsed Hodgkin's disease.
Schmitz N; Glass B; Dreger P; Haferlach T; Horst HA; Ollech-Chwoyka J; Suttorp M; Gassmann W; Löffler H
Ann Hematol; 1993 May; 66(5):251-6. PubMed ID: 8099502
[TBL] [Abstract][Full Text] [Related]
17. High-dose chemotherapy with BEAC regimen and autologous bone marrow transplantation for intermediate grade and immunoblastic lymphoma: durable complete remissions, but a high rate of regimen-related toxicity.
van Besien K; Tabocoff J; Rodriguez M; Andersson B; Mehra R; Przepiorka D; Dimopoulos M; Giralt S; Suki S; Khouri I
Bone Marrow Transplant; 1995 Apr; 15(4):549-55. PubMed ID: 7655380
[TBL] [Abstract][Full Text] [Related]
18. High-dose cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation in patients with lymphoid malignancies who have received dose-limiting radiation therapy.
Weaver CH; Appelbaum FR; Petersen FB; Clift R; Singer J; Press O; Bensinger W; Bianco J; Martin P; Anasetti C
J Clin Oncol; 1993 Jul; 11(7):1329-35. PubMed ID: 8315430
[TBL] [Abstract][Full Text] [Related]
19. Treatment of relapsed and refractory Hodgkin's disease with high dose chemotherapy and autologous bone marrow transplantation.
Brice P; Gisselbrecht C; Ferme C; Lepage E; Baruchel A; Marolleau JP; Gerota O; Boiron M
Nouv Rev Fr Hematol (1978); 1991; 33(3):267-72. PubMed ID: 1956765
[TBL] [Abstract][Full Text] [Related]
20. High-dose chemotherapy and autologous peripheral blood progenitor cell transplant for the treatment of Hodgkin's disease.
Weaver CH; Schwartzberg L; Li W; Hazelton B; West W
Bone Marrow Transplant; 1996 May; 17(5):715-21. PubMed ID: 8733687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
